Risk factors
Metagenomi Therapeutics (MGX) risk factors
Item 1A of every Metagenomi Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors88 risks4 new11 dropped20 reworded
Tax exposure now highlights OBBBA and Section 174 treatment of research expenses, including potential cash-flow effects.
Filed Mar 05, 2026 - FY2024 10-K risk factors95 risks
As an early-stage genome editing company with $248.3M in cash and a $223.0M accumulated deficit, risks center on unproven technology, substantial funding needs, and clinical trial execution.
Filed Mar 17, 2025